Replies

"The surface of the Ebola virus is covered with glycoprotein (GP) [joined together proteins that contain a carbohydrate as the nonprotein component], which binds host cells, allowing the virus to enter. Ebola is an RNA-based virus, which means its genetic information is stored in RNA, not DNA. Thus, it has to use a special enzyme (an RNA-dependent RNA polymerase [enzymes that catalyze the formation of polynucleotides of DNA or RNA using an existing strand of DNA or RNA as a template])".

I believe that two forms are created. One to distract and occupy the immune system while the other does the dirty work.

source

The description of the glycoprotein intrigued me because I have read of the harm that glycation does. Glycation is not the same as glycosylation. Glycation is

the haphazard bonding of
- glucose molecules,
- sugars, and
- similar chemicals
with
- proteins,
- polynucleotides, and
- lipids.

Bonding with yet other protein molecules can occur leading to advanced glycation endproducts (AGEs). There the immune system regards these glycated proteins as foreign and develops antibodies against them and can result in a defective immune system directing antibodies against the host's own tissues. It is thought to be the cause of autoimmune disorders.

The point is: the ebola virus is bad but like all others operates within the confines of biochemistry. It will be defeated. But in the meantime . . . .

(We put men on the Moon in relative short order. We can defeat Ebola and other hemorrhagic diseases.)

WOC - I know you know most of this, but I'm re-posting for benefit of all ...

Trying to get a reliable Quick-Test for EBOLA - [10/03/2014] This New Ebola Test Is As Easy As a Pregnancy Test, So Why Aren’t We Using It?

Dr. Bob Garry, a scientist at Tulane University, is working harder than ever to get one possible solution—a rapid diagnostic test approved.
[Regarding the present, lengthy waiting for symptoms to show ... and the current tests]
It’s the breakdown in care caused by delay that Garry and his team are hoping to fix. The scientists began working in West Africa roughly 10 years ago on another fever called Lassa. Over the course of a few years, they developed a rapid diagnostic test that allowed doctors to give patients a diagnosis on the spot. When the first cases of Ebola began popping up in West Africa, Garry and his team began “fortifying” existing labs they had in the area. In the creation of the Lassa fever test strips, they had also made a similar, but separate, Ebola test. But without any presence of Ebola in the region until this year, they were unable to test them until now.
The value of the rapid diagnostic test lies in its simplicity. It consists of a small white lancet, which requires just a small drop of blood. In 15 minutes or less, a positive or negative line will appear on the test, indicating Ebola positive or negative. "They work like pregnancy tests except its blood," says Garry.
“What our tests would permit one to do is to basically see if a person has Ebola on the spot,” Garry tells me. “They are not perhaps as sensitive as a PCR. That’s a very sophisticated test, but they don’t really have to be. What we’re most interested in doing is coming out with a test that could detect when someone is infectious, immediately.”

[10/06/2014] U.S. Ebola patient receives experimental drug ("Brincidofovir" also called "CMX-001") from Chimerix

CMX-001 is a compound called a nucleotide analog. Its molecules behave enough like those that form the genetic material (nucleotides) of viruses such as Ebola that the microbes incorporate it into their DNA or RNA, a sister molecule.
But CMX-001 is different enough that, once incorporated, it prevent a virus's genetic material from replicating. That stops the virus from spreading throughout the body.

[10/07/2014] Go Inside San Diego Lab Working to Cure Ebola Virus

[Paraphrasing ...] A La Jolla lab is on the front lines of the fight against the Ebola Virus. Dr. Erica Ollmann Saphire is part of the [Scripps La Jolla] team spanning 25 labs across the globe that is making images of how the virus works. [The La Jolla team's] work has led to a medicine taken [so far] by two Americans infected with Ebola.
[08/04/2014] The Sorrento Valley lab, Mapp Biopharmaceutical uses images created at Scripps [La Jolla] to come up with the experimental medicine called Z-Mapp.
In the video of Dr. Erica Ollmann Saphire, she explains the basic working of Z-Mapp while holding up a molecular model. The Blue antibody at the top of the model, tags the Ebola virus for destruction by the immune system. The Green antibody and the Yellow antibody neutralize the Ebola virus infection. These two antibodies lock the virus' machinery together so the machinery (see above) cannot unravel and drive into a cell.

[10/16/2014] Israeli Company Ready To Mass Produce Ebola Vaccine

"an Israeli biotech company named Protalix is ready to replenish supplies of the experimental Ebola vaccine, ZMapp"

Handy wipes for use of public facilities: Clorox Bleach Germicidal Wipes